stonks4u
Sign up free
CTXR logo

CTXR Citius Pharmaceuticals, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.76
+0.02 (+3.00%)

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within i…

Market Cap: $8.44Mwww.citiuspharma.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

150
7097123150
Aug 12Aug 14

Quote

Day Range
$0.73 – $0.79
52-Week Range
$0.47 – $2.19
Volume
$523.9K
Market Cap
$8.44M
50-Day Avg
$0.58
200-Day Avg
$0.81
Prev Close
$0.73
Open
$0.75

Valuation & Ratios

P/E Ratio
-0.37
EPS
$-3.38
P/B Ratio
0.20
P/S Ratio
0.00
Debt/Equity
0.03
Current Ratio
0.62
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-55.4%
Return on Assets
-28.6%
FCF Yield
-193.5%
EV/EBITDA
-0.30

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-37.43M$-3.38
2024$0.00$-39.14M$-5.97
2023$0.00$-32.54M$-5.57
2022$0.00$-33.64M$-5.76
2021$0.00$-23.13M$-5.64

Social Signal Score

58
5d
58
3 mentions
—
30d
58
3 mentions
—
60d
58
3 mentions
—
90d
58
3 mentions
—
news: 3

Earnings

1of 8 quarters beat consensus

Typical surprise -136.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 14$-0.34 vs $-0.36beat
  • Fri, May 15$-0.95 vs $-0.28miss
  • Fri, Feb 13$-0.38 vs $0.43miss
  • Thu, Dec 25$-0.44 vs $-0.24miss
  • Tue, Aug 12$-0.80 vs $-0.24miss
  • Wed, May 14$-1.27 vs $-1.08miss

Estimates and results for CTXR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

CTXRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (3)

  • Newsprnewswire.com·23h ago·Neutral

    …ical affairs organizations deployed nationwide CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).

    View source ↗
  • Newsprnewswire.com·23h ago·Neutral

    …the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update.

    View source ↗
  • Newsprnewswire.com·3d ago·Positive

    Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D.

    View source ↗